Breast Cancer Research and Treatment

, Volume 129, Issue 2, pp 411–419

Inhibition of the c-fms proto-oncogene autocrine loop and tumor phenotype in glucocorticoid stimulated human breast carcinoma cells

  • Eugene P. Toy
  • Tiffany Lamb
  • Masoud Azodi
  • William J. Roy
  • Ho-Hyung Woo
  • Setsuko K. Chambers
Preclinical Study

DOI: 10.1007/s10549-010-1247-7

Cite this article as:
Toy, E.P., Lamb, T., Azodi, M. et al. Breast Cancer Res Treat (2011) 129: 411. doi:10.1007/s10549-010-1247-7

Abstract

The c-fms proto-oncogene encoded CSF-1 receptor and its ligand represent a feedback loop, which in a paracrine manner, is well known to promote spread of breast cancers. The role of the autocrine feedback loop in promotion of breast tumor behavior, in particular in vitro, is less well understood. The physiologic stimulation of c-fms expression by glucocorticoids (GCs) in vitro and in vivo magnifies the tumor promoting effect seen in these cells from activated c-fms signaling by CSF-1. Targeted molecular therapy against c-fms could therefore abrogate both complementary feedback loops. Using breast cancer cells endogenously co-expressing receptor and ligand, we used complementary approaches to inhibit c-fms expression and function within this autocrine pathway in the context of GC stimulation. Silencing RNA (shRNA), antisense oligonucleotide therapy (AON), and inhibition of c-fms signaling, were all used to quantitate inhibition of GC-stimulated adhesion, motility, and invasion of human breast cancer cells in vitro. shRNA to c-fms downregulated GC-stimulated c-fms mRNA by fourfold over controls, correlating with over twofold reduction in cellular invasiveness. AON therapy was also able to inhibit GC stimulation of c-fms mRNA, and resulted in threefold less invasiveness and 1.5 to 2-fold reductions in adhesion and motility. Finally, the small-molecule c-fms inhibitor Ki20227 was able to decrease in a dose–response manner, breast cancer cell invasion by up to fourfold. Inhibition of this receptor/ligand pair may have clinical utility in inhibition of the autocrine as well as the known paracrine interactions in breast cancer, thus further supporting use of targeted therapies in this disease.

Keywords

Breast cancerInvasionc-fmsProto-oncogeneGlucocorticoids

Abbreviations

Dex

Dexamethasone

FCS

Fetal calf serum

ON

Overnight

AON

Antisense oligonucleotide

GC

Glucocorticoid

qRT-PCR

Quantitative real time reverse transcriptase polymerase chain reaction

siRNA

Silencing RNA

shRNA

Small hairpin RNA

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Eugene P. Toy
    • 1
    • 5
  • Tiffany Lamb
    • 4
  • Masoud Azodi
    • 2
  • William J. Roy
    • 3
  • Ho-Hyung Woo
    • 4
  • Setsuko K. Chambers
    • 4
  1. 1.Departments of Obstetrics and Gynecology, Division of Gynecologic OncologyUniversity of RochesterNYUSA
  2. 2.Department of Obstetrics and GynecologyYale University School of MedicineNew HavenUSA
  3. 3.GYN Oncology at the Cancer CenterCredentialed by MD Anderson Physicians NetworkMobileUSA
  4. 4.Arizona Cancer CenterUniversity of ArizonaTucsonUSA
  5. 5.Gynecologic Oncology AssociatesUniversity of RochesterRochesterUSA